Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study

Younak Choi; Do-Youn Oh; Kyubo Kim; Eui Kyu Chie; Tae-Yong Kim; Kyung-Hun Lee; Sae-Won Han; Seock-Ah Im; Tae-You Kim; Sung Whan Ha; Yung-Jue Bang

doi:10.4143/crt.2015.226

Articles

Page Path: HOME > Cancer Res Treat > Volume 48(3); 2016 > Article

Original Article Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study: Younak Choi, MD^1,a, Do-Youn Oh, MD, PhD^1,2, Kyubo Kim, MD, PhD³, Eui Kyu Chie, MD, PhD³, Tae-Yong Kim, MD, PhD^1,2, Kyung-Hun Lee, MD, PhD^1,2, Sae-Won Han, MD, PhD^1,2, Seock-Ah Im, MD, PhD^1,2, Tae-You Kim, MD, PhD^1,2, Sung Whan Ha, MD, PhD³, Yung-Jue Bang, MD, PhD^1,2; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2016;48(3):1045-1055.
DOI: https://doi.org/10.4143/crt.2015.226
Published online: October 16, 2015

¹Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea

²Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea

³Department of Radiation Oncology, Seoul National University Hospital, Seoul, Korea

Correspondence: Do-Youn Oh, MD, PhD Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
Tel: 82-2-2072-0701 Fax: 82-2-762-9662 E-mail: ohdoyoun@snu.ac.kr

^aPresent address: Department of Internal Medicine, Dongguk University Gyeongju Hospital, Gyeongju, Korea

• Received: June 24, 2015 • Accepted: September 30, 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

13,425 Views
138 Download
11 Web of Science
12 Crossref
10 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
The optimal treatment strategy for locally advanced pancreatic cancer (LAPC), particularly the role of concurrent chemoradiotherapy (CCRT), remains debatable. We compared the clinical outcomes of CCRT and palliative chemotherapy alone (CA) in patients with unresectable LAPC.
Materials and Methods
Patients with LAPC who were consecutively treated between 2003 and 2010 were included. Resectability was evaluated according to National Comprehensive Cancer Network ver. 1.2012. The clinical outcomes for each treatment group (CCRT vs. CA) were evaluated retrospectively.
Results
Sixty-three patients (58.9%) and 44 patients (41.1%) were treated with CCRT and CA, respectively. The CCRT cohort included patients who were treated with CCRT with or without chemotherapy backbone (CCRT alone, induction chemotherapy-CCRT, CCRT-maintenance chemotherapy, and induction-CCRT-maintenance chemotherapy). Median progression-free survival (PFS) and overall survival (OS) of all patients were 7.2 months and 13.1 months. PFS of the CCRT and CA groups was 9.0 months and 4.4 months, respectively (p=0.020). OS of the CCRT and CA groups was 15.4 months and 9.3 months, respectively (p=0.011). In multivariate analysis, the adjusted hazard ratio of CCRT was 0.536 (p=0.003) for OS and 0.667 (p=0.078) for PFS. Although the pattern of failure was similar in the CCRT and CA groups, the times to both local and distant failure were significantly longer in the CCRT group.
Conclusion
In patients with unresectable LAPC, those who underwent CCRT during their entire treatment courses had longer OS than patients treated with chemotherapy alone.
Key words: Pancreatic neoplasms, Chemoradiotherapy, Prognosis

Introduction

Pancreatic cancer (PC) is the fourth most common cause of cancer death in both Asian and western countries [1]. At the time of diagnosis, less than 20% of patients are eligible for curative surgery [2]. Among patients with initially inoperable PC, approximately 30% of patients present with locally advanced disease without distant metastasis [3]. PC has a dismal prognosis, with a 5-year overall survival (OS) rate of 5% [4].

The optimal treatment strategy for locally advanced pancreatic cancer (LAPC) is still controversial, and the role of local control by concurrent chemoradiotherapy (CCRT) has not been established. Most clinical trials in the setting of palliative chemotherapy in PC have included both LAPC patients and metastatic PC patients, altogether, and used the extent of disease as a stratification factor.

The superiority of CCRT to radiation alone was proven in 1981 [3]. Although the Gastrointestinal Tumor Study Group (GITSG) reported a higher efficacy of CCRT than chemotherapy alone (CA) in the 1980’s, the superiority of CCRT and CA continues to be debated [5,6]. After the introduction of gemcitabine for treatment of advanced PC, treatment with gemcitabine alone resulted in longer survival than 5-fluorouracil (5-FU) based CCRT followed by maintenance gemcitabine (13 months vs. 8.6 months) in the FFCD-SFRO trial [7].

In contrast, in treatment with gemcitabine plus radiation longer survival was achieved compared to gemcitabine alone (11.1 months vs. 9.2 months) in the ECOG E4201 trial [8].

Induction chemotherapy prior to CCRT was introduced for achievement of both systemic and local control of possible unrecognized micro-metastases and to effectively identify the patients who might benefit from CCRT after induction chemotherapy [9,10].

The introduction of new radiosensitizing agents with advanced radiotherapy techniques reduced toxicities; however, consensus regarding efficacy is still elusive [11,12]. Gemcitabine was reported to be a more potent radiosensitizer than 5-FU [13], and better outcomes were reported for capecitabine, another radiosensitizer, than gemcitabine [14]. However, those findings are insufficient to support a general consensus regarding the optimal treatment for LAPC.

Therefore, this study was conducted to evaluate the effects of adding CCRT to a chemotherapy backbone in LAPC.

Materials and Methods

1. Study patients

LAPC patients who were consecutively treated between 2003 and 2010 were included. Eligible patients had (1) histologically confirmed pancreatic adenocarcinoma, (2) no radiographic evidence of distant metastases, and (3) radiographic evidence of unresectability.

All computed tomography/magnetic resonance imaging image were reviewed for the unresectability, following the guidelines for LAPC of the National Comprehensive Cancer Network (NCCN) ver. 1.2012 [15]. Tumors met the criteria: tumors invaded or encased the aorta or encased the celiac axis or superior mesenteric artery by more than 180˚ (abutted celiac axis at any degree in pancreatic head cancer) or demonstrated unreconstructable occlusion of the superior mesenteric vein or portal vein or extended to lymph nodes beyond the field of resection.

2. Study methods

1) Treatment cohort

Patients who underwent CA during the entire treatment course were included in the CA group. Patients who underwent CCRT during the entire treatment course were included in the CCRT group.

2) Response evaluation

Objective tumor response was evaluated according to the Response Evaluation Criteria In Solid Tumors (RECIST) ver. 1.1.

Body mass index (BMI) was calculated as body weight divided by height² (kg/m²) measured the day of the first dose of chemotherapy. Tumors were staged according to the American Joint Committee on Cancer (AJCC) seventh edition.

3. Statistical analysis

OS, progression-free survival (PFS), best response, pattern of failure, and toxicities were evaluated according to treatment groups. OS was defined as the period from the start of treatment to death from any cause. PFS was defined as the period from the start of treatment to the progression of disease or death from any cause, with censoring of patients who are lost to follow-up.

The median OS and PFS were calculated using the Kaplan-Meier method. Between-group differences in demographic and clinical data were evaluated using Fisher exact test for categorical variables. The effect of multiple factors on survival, the hazard ratio (HR) and its 95% confidence interval (CI) were evaluated using Cox proportional hazards models. Each variable that was likely to be associated with survival, based on p ≤ 0.1 in the univariate analysis, was evaluated in the multivariate analysis. The survival of the two groups was compared using the log-rank test. All tests were 2-sided, and p ≤ 0.05 was considered statistically significant. Statistical analyses were performed using SPSS ver. 19.0 (IBM Co., Armonk, NY).

4. Ethics

This study was reviewed and approved by the Institutional Review Board of Seoul National University Hospital (IRB No. H-1307-146-507). All studies were conducted according to ethical guidelines (Declaration of Helsinki) for biomedical research.

Results

1. Patient characteristics

A total of 107 patients with LAPC were identified retrospectively; their characteristics by treatment groups are shown in Table 1. The median age was 60.7 years (range, 35.2 to 84.0 years) and most patients (88.8%) had a performance status of 0 or 1. Thirty-one patients (29.0%) had T3 lesions and 76 patients (71.0%) had T4 lesions, and 45 patients (42.1%) had positive lymph nodes. Primary tumor sites were equally distributed in the head (51.4%) and body (48.6%) of the pancreas. Seventy-three patients (68.2%) had primary tumors larger than 3 cm. BMI distributions were BMI < 20.0 (29.0%); 20.0 ≤ BMI < 25.0 (57.0%); and BMI ≥ 25.0 (14.0%).

2. Treatment regimen

Flow diagram for the study cohort is shown in Fig. 1 and treatments are summarized in Table 2. Sixty-three patients (58.9%) underwent CCRT and 44 patients (41.1%) underwent CA.

1) CCRT cohort

(1) Induction chemotherapy

Among the CCRT group, 36 patients (57.1%) received a median of three cycles of induction chemotherapy (range, 1 to 9) prior to CCRT. The most commonly selected induction agents were gemcitabine-based doublets.

(2) CCRT

The prearranged total dose was 55.8 Gy/31 fractions delivered five times weekly, composed of 45 Gy/25 fractions delivered to the entire region and 10.8 Gy/6 fractions as a booster. Most patients (n=56, 88.9%) received a radiation dose ≥ 50 Gy. Median total delivered radiation dose was 55.8 Gy (range, 32.4 to 59.4 Gy) delivered as 1.8 Gy per fraction (range, 1.6 to 2.0 Gy) over 6 weeks (median, 6.1 weeks; range 2.6 to 8.1 weeks). Radiosensitizers used during CCRT were gemcitabine (n=17, 27.0%), 5-FU (n=16, 25.4%), and capecitabine (n=30, 47.6%).

(3) Maintenance chemotherapy

Patients without progression after CCRT received additional maintenance chemotherapy (n=44, 69.8%) using a median of three cycles (range, 1 to 17 cycles). The most frequently used maintenance chemotherapy agents were also gemcitabine-based regimens (n=38, 86.3%).

2) CA cohort

Among the patients in the CA group, gemcitabine-based regimen was used in 97.7% of patients. Median chemotherapy cycle and dose intensity were three cycles (range, 1 to 18 cycles) and 100% (range, 60% to 100%), respectively.

The baseline characteristics showed a similar distribution in the CCRT and CA groups (Table 1).

3. Treatment outcomes

The median duration of follow-up for all patients was 12.6 months (range, 2.0 to 58.3 months), and the median OS and PFS were 13.1 months (95% CI, 11.6 to 14.6 months) and 7.2 months (95% CI, 6.2 to 8.3 months), respectively. Two patients who underwent CCRT after first-line failure were excluded from the analysis of PFS for first-line treatment.

4. Outcomes analysis by treatment group

First-line treatment outcomes of CCRT and CA groups are summarized in Table 3.

1) Response

In the CCRT group, three patients (4.9%) had complete response (CR), 18 (29.5%) had partial response (PR), and 37 (60.7%) had stable disease (SD). In the CA group, one patient (2.3%) had CR, seven (15.9%) had PR, and 18 (40.9%) had SD.

2) OS

The median OS was 15.4 months (95% CI, 13.2 to 17.6 months) in the CCRT group and 9.3 months (95% CI, 6.6 to 12.0 months) in the CA group (p=0.011) (Table 4, Fig. 2A). The 1-year OS was 69.1% in the CCRT group and 37.9% in the CA group. The median OS of patients who underwent CCRT alone, induction-CCRT, CCRT-maintenance, and induction-CCRT-maintenance was 10.9 months (95% CI, 6.4 to 15.4 months), 9.2 months (95% CI, 1.7 to 16.8 months), 17.0 months (95% CI, 14.3 to 19.8 months), and 17.0 months (95% CI, 15.1 to 18.9 months), respectively (p=0.010). CCRT with induction chemotherapy did not differ significantly from CCRT without induction chemotherapy in OS (16.4 months vs. 13.6 months; HR, 0.840; 95% CI, 0.492 to 1.435; p=0.524). However, CCRT with maintenance chemotherapy resulted in significantly longer OS than CCRT without maintenance chemotherapy (17.0 months vs. 9.2 months; HR, 0.449; 95% CI, 0.251 to 0.801; p=0.007).

3) PFS

The median PFS was 9.0 months (95% CI, 7.0 to 11.0 months) in the CCRT group and 4.4 months (95% CI, 0.9 to 8.0 months) in the CA group (p=0.020). Six-month PFS was 68.3% and 47.4% and 1-year PFS was 28.6% and 13.1%, respectively (Table 4, Fig. 2B). The PFS of patients who underwent CCRT alone, induction-CCRT, CCRT-maintenance, and induction-CCRT-maintenance was 3.0 months (95% CI, 2.3 to 3.7 months), 5.3 months (95% CI, 4.5 to 6.1 months), 6.9 months (95% CI, 2.4 to 11.5 months), and 11.4 months (95% CI, 10.2 to 12.7 months), respectively (p < 0.001). The use of induction and maintenance chemotherapy prolonged PFS (10.8 months vs. 4.7 months; HR, 0.449; 95% CI, 0.261 to 0.773; p=0.004) and (10.8 months vs. 4.5 months; HR, 0.322; 95% CI, 0.177 to 0.585; p < 0.001), respectively. Only one patient in the CCRT group converted to resectability, underwent margin-negative resection after CCRT, and had an OS of 17.0 months and PFS of 6.9 months.

4) Patterns of failure

The pattern of progression (local failure and/or distant metastasis) is shown in Table 4. Among assessable patients, the frequency of local failure, with or without distant progression, did not differ; 54.9% and 58.6% in the CCRT and CA groups, respectively (p=0.817). However, median time to local progression was longer, by 6.8 months, in the CCRT group than in the CA group (p < 0.001). The frequency of systemic failure, with or without local progression, was also similar, 58.8% in the CCRT group and 58.6% in the CA group (p=1.000). Median time to distant progression was also longer, by 2.8 months, in the CCRT group than in the CA group (p=0.001) (Table 4). However, in comparison of the CCRT alone and CA groups, no significant difference was found in survival and pattern of failure (OS: HR, 0.880; p=0.718; time to local failure: HR, 1.255; p=0.665; time to systemic failure: HR, 0.749; p=0.654). In all patients, the most frequent sites of distant failure were liver (30.9%), peritoneum (27.2%), and lung (12.3%).

5. Analysis of prognostic factors

Table 5 shows the results of the analysis of possible prognostic factors for OS. In the univariate analysis, BMI (p=0.021), CCRT (p=0.011), carbohydrate antigen 19-9 (CA19-9) (p=0.007), and albumin (p < 0.001) showed significant association with OS. In the multivariate analysis, elevated CA19-9 (HR, 1.877; 95% CI, 1.077 to 3.272; p=0.026) and decreased albumin levels (HR, 3.148; 95% CI, 1.863 to 5.320; p < 0.001) conferred a higher risk for death, whereas CCRT (HR, 0.536; 95% CI, 0.355 to 0.809; p=0.003) significantly lowered the risk.

In the univariate analysis, the significant prognostic factors for PFS were T stage (p=0.001), N stage (p=0.021), initial BMI (p=0.030), and CCRT (p=0.020). In the multivariate analysis, T4 (HR, 0.504; 95% CI, 0.308 to 0.825; p=0.006), positive lymph node (HR, 1.664; 95% CI, 1.049 to 2.639; p=0.030), and normal range of initial BMI (HR, 0.590; 95% CI, 0.350 to 0.995; p=0.048) showed association with PFS. CCRT (HR, 0.667; 95% CI, 0.426 to 1.046; p=0.078) and decreased albumin (HR, 1.662; 95% CI, 0.931 to 2.969; p=0.086) tended to showed association with longer and shorter PFS, respectively (Table 6).

Discussion

The question of whether CCRT or CA is superior for LAPC has been debated for decades. In this study, we demonstrated an advantage of CCRT. Using multivariate analysis, we found that addition of CCRT in the chemotherapy backbone had excellent prognostic implications for treatment of LAPC patients. Further examination showed that better outcomes could be achieved by sequential treatment of CCRT-maintenance chemotherapy.

In addition, although the CCRT and CA groups showed similar patterns of failure, time to distant progression and to time to local progression were also significantly longer in the CCRT group.

Previous clinical trials focusing on combined radiosensitizers have reported conflicting results. Although gemcitabine was reported to be a more potent radiosensitizer than 5-FU [13], these results were inconsistent [11,16]. In the SCALOP trial, the use of capecitabine, a radiosensitizer, resulted in a better outcome than gemcitabine [14]. However, further controlled trials comparing the efficacy of radiosensitizers are needed.

For more than 30 years, many studies have investigated the optimal treatment of LAPC. Some studies supported the superiority of CCRT over CA [5,8,9], but others did not agree with CCRT’s superiority [7,17]. In this study, longer OS was observed with CCRT than with CA and longer PFS by use of an induction and/or maintenance chemotherapy backbone in the CCRT regimen. Of note, the median PFS of patients treated with CCRT alone was only 3.0 months. In previous studies of LAPC, the use of CCRT after disease control with induction chemotherapy prolonged both OS and PFS [9,18]. These findings support the hypothesis that combined chemotherapy can suppress distant metastases caused by early micro-metastases [19]. Based on analysis of a subgroup of patients of the LAP07 trial, a recent report showed that detection of circulating tumor cells (CTCs) for evaluation of micrometastatic disease was a promising prognostic tool. CTC positivity at baseline and/or at 2 months was associated with a shorter survival (p=0.01) [10].

Among the treatment modalities for PC, resection with a negative margin provides the most favorable prognosis. Because some studies reported their experience with R0 resection in LAPC patients, after pre-operative CCRT allowed down-staging, interest in the neoadjuvant role of CCRT for patients with LAPC and borderline resectable pancreatic cancer (BRPC) patient is increasing [20].

We observed that CCRT, when added to a combined chemotherapy backbone, is clearly beneficial for LAPC patients. We demonstrated that maintenance chemotherapy lengthened both OS and PFS, but we could not prove the efficacy of induction chemotherapy.

The strengths of this study were (1) only initially unresectable LAPC patients were included. BRPC patients with a higher possibility of R0 resection and better prognosis were excluded. (2) We avoided possible confounding by FOLFIRINOX, which is the most powerful first-line treatment regimen and has no credible efficacy data as second-line treatment. The limitations of this trial originated from the retrospective design. We could not obtain reliable data on toxicities.

Conclusion

In conclusion, our study strongly suggests that strengthening the early treatment by addition of CCRT in the chemotherapy backbone during treatment of LAPC patients conferred better treatment outcomes. Further controlled trials are warranted to evaluate the role of CCRT and the efficacy of combined agents.

NOTES

Conflict of interest relevant to this article was not reported.

Fig. 1.

Flow diagram for the study cohort. LAPC, locally advanced pancreatic cancer; CCRT, concurrent chemoradiotherapy, CA, chemotherapy alone.

Fig. 2.

Overall survival (OS) and progression-free survival (PFS) by first-line treatment modality. (A) Median OS was 15.4 months (95% confidence interval [CI], 13.2 to 17.6 months) in the concurrent chemoradiotherapy (CCRT) group and 9.3 months (95% CI, 6.6 to 12.0 months) in the chemotherapy alone (CA) group (p=0.011). (B) Median PFS was 9.0 months (95% CI, 7.0 to 11.0 months) in the CCRT group and 4.0 months (95% CI, 1.6 to 6.3 months) in the CA group (p=0.010).

Table 1.

Clinical characteristics by treatment groups

Characteristic	CCRT vs. CA		Total (n=107)	p-value^a)
Characteristic	CCRT (n=63)	CA (n=44)	Total (n=107)	p-value^a)
Sex
Male	33 (52.4)	20 (45.5)	53 (49.5)	0.557
Female	30 (47.6)	24 (54.5)	54 (50.5)
Age (yr)
≥ 60	30 (47.6)	29 (65.9)	59 (55.1)	0.076
< 60	33 (52.4)	15 (34.1)	48 (44.9)
Performance
0-1	57 (86.4)	38 (86.4)	95 (88.8)	0.546
≥ 2	6 (9.6)0	6 (13.6)	12 (11.2)
T stage
3	14 (22.2)	17 (38.6)	31 (29.0)	0.084
4	49 (77.8)	27 (61.4)	76 (71.0)
N stage
0	41 (65.1)	21 (47.7)	62 (57.9)	0.111
1	22 (34.9)	23 (52.3)	45 (42.1)
Site
Head	29 (46.0)	26 (59.1)	55 (51.4)	0.239
Corpse	34 (54.0)	18 (40.9)	52 (48.6)
Size (cm)
≥ 3	41 (65.1)	32 (72.7)	73 (68.2)	0.527
< 3	22 (34.9)	12 (27.3)	34 (31.8)
Initial BMI (kg/m²)
< 20.0	19 (30.2)	12 (27.3)	31 (29.0)	0.924
20.0-24.9	36 (57.1)	25 (56.8)	61 (57.0)
≥ 25.0	8 (12.7)	7 (15.9)	15 (14.0)
CA19-9
Elevated	46 (73.0)	37 (84.1)	83 (77.6)	0.240
Normal	17 (27.0)	7 (15.9)	24 (22.4)
Albumin
Decreased	11 (17.5)	10 (22.7)	21 (19.6)	0.622
Normal	52 (82.5)	34 (77.3)	86 (80.4)
No. of chemotherapy regimens
1	31 (49.2)	29 (65.9)	60 (56.1)	0.114
≥ 2	32 (50.8)	15 (34.1)	47 (43.9)

Values are presented as number (%). CCRT, concurrent chemoradiotherapy; CA, chemotherapy alone; BMI, body mass index; CA19-9, carbohydrate antigen 19-9.

^a) Fisher exact test was performed.

Table 2.

Details of treatment regimens

Characteristic	No. of patients (%)
CCRT group (n=63)
Induction chemotherapy (n=63)
Administered	36 (57.1)
Not administered	27 (42.9)
DI of induction chemotherapy (%) (n=36)
100	18 (50.0)
< 100	18 (50.0)
Agents of induction chemotherapy (n=36)
Gemcitabine/cisplatin	31 (86.1)
Gemcitabine/capecitabine	1 (2.8)
Gemcitabine/oxaliplatin	1 (2.8)
Gemcitabine alone	3 (8.3)
Radiosensitizer (n=63)
Gemcitabine	17 (27.0)
5-FU	16 (25.4)
Capecitabine	30 (47.6)
Total radiation dose (Gy) (n=63)
< 50	7 (11.1)
50-60	56 (88.9)
Radiation dose per fraction (Gy) (n=63)
1.6	1 (1.6)
1.8	52 (82.5)
2	10 (15.9)
Maintenance chemotherapy (n=63)
Administered	44 (69.8)
Not administered	19 (30.2)
DI of maintenance chemotherapy (%) (n=44)
100	23 (52.3)
< 100 (70-87.5)	21 (47.7)
Agents of maintenance chemotherapy (n=44)
Gemcitabine/cisplatin	9 (20.4)
Gemcitabine/capecitabine	3 (6.8)
Gemcitabine/5-FU	1 (2.3)
Gemcitabine alone	25 (56.8)
5-FU/leucovorin	4 (9.1)
5-FU/cisplatin	1 (2.3)
Capecitabine alone	1 (2.3)
CA group (n=44)
DI of chemotherapy (%) (n=44)
100	28 (63.6)
< 100 (70-87.5)	16 (36.4)
Agents of chemotherapy (n=44)
Gemcitabine/cisplatin	18 (40.9)
Gemcitabine/capecitabine	10 (22.7)
Gemcitabine/oxaliplatin	4 (9.1)
Gemcitabine/erlotinib	2 (4.5)
Gemcitabine/capecitabine/erlotinib	1 (2.3)
Gemcitabine/S-1	1 (2.3)
Gemcitabine alone	7 (15.9)
S-1	1 (2.3)

CCRT, concurrent chemoradiotherapy; 5-FU, 5-fluorouracil; DI, dose intensity; CA, chemotherapy alone.

Table 3.

Response to first-line treatment

Characteristic	No. of patients (%)
CCRT group (n=61)
Treatment scheme (n=61)
CCRT alone	10 (16.4)
Induction-CCRT	8 (13.1)
CCRT-maintenance	15 (24.6)
Induction-CCRT-maintenance	28 (45.9)
BR to induction chemotherapy (n=36)
PR	5 (13.9)
SD	31 (86.1)
BR to CCRT (n=61)
CR	1 (1.6)
PR	15 (24.6)
SD	39 (64.0)
PD	6 (9.8)
BR to entire CCRT regimen (n=61)
CR	3 (4.9)
PR	18 (29.5)
SD	37 (60.7)
PD	3 (4.9)
Pattern of failure (n=59)
Local	21 (35.6)
Systemic	23 (39.0)
Both	7 (11.9)
NA	8 (13.5)
CA group (n=44)
BR to first-line treatment (n=44)
CR	1 (2.3)
PR	7 (15.9)
SD	18 (40.9)
PD	12 (27.3)
NA	6 (13.6)
Pattern of failure (n=43)
Local	12 (27.3)
Systemic	13 (29.5)
Both	4 (9.1)
NA	14 (34.1)

CCRT, concurrent chemoradiotherapy; BR, best response; PR, partial response; SD, stable disease; CR, complete response; PD, progressive disease; NA, not assessable; CA, chemotherapy alone.

Table 4.

Summary of response and survival by treatment groups

Characteristic	CCRT vs. CA (n==105)		p-value
Characteristic	CCRT (n=61)	CA (n=44)	p-value
First-line treatment	61	44
Best response
ORR	21 (34.4)	8 (18.2)	0.079^a)
DCR	58 (95.1)	26 (59.1)	< 0.001^a)
Pattern of PD (of accessible patients) (n=82)
Local	28 (54.9)	17 (58.6)	0.817^a)
Systemic	30 (58.8)	17 (58.6)	1.000^a)
Median survival (mo)
First-line PFS (95% CI)	9.0 (7.0-11.0)	4.4 (0.9-8.0)	0.020^b)
Time to local failure (95% CI) (n=46)	10.5 (8.5-12.4)	3.7 (1.4-5.9)	0.001^b)
Time to distant failure (95% CI) (n=48)	7.8 (5.1-10.5)	5.0 (1.6-8.4)	0.001^b)
OS (95% CI) (n=107)	15.4 (13.2-17.6)	9.3 (6.6-12.0)	0.011^b)

Values are presented as number (%). CCRT, concurrent chemoradiotherapy; CA, chemotherapy alone; ORR, objective response rate; DCR, disease control rate; PD, progression; PFS, progression-free survival; CI, confidential interval; OS, overall survival.

^a) Fisher exact test was performed,

^b) Log-rank test was performed.

Table 5.

Analysis of potential prognostic factors for overall survival

Clinical factor	mOS (mo)	Univariate analysis			Multivariate analysis
Clinical factor	mOS (mo)	HR	95% CI	p-value^a)	HR	95% CI	p-value^b)
Age (yr)
≥ 60	-	1.135	0.759-1.698	0.536	-	-	-
< 60	-	1			-
Performance
≥ 2	-	1.434	0.760-2.707	0.266	-	-	-
0-1	-	1			-
T stage
4	-	0.961	0.616-1.499	0.861	-	-	-
3	-	1			-
N stage
1	-	1.165	0.776-1.749	0.462	-	-	-
0	-	1			-
Site
Corpse	-	0.816	0.547-1.217	0.319	-	-	-
Head	-	1			-
Size (cm)
≥ 3	-	1.302	0.841-2.014	0.236	-	-	-
< 3	-	1			-
Initial BMI (kg/m²)				0.021			0.097
< 20.0	10.7	1		Reference	1		Reference
20.0-24.9	14.2	0.532	0.337-0.840	0.007	0.601	0.374-0.965	0.035
≥ 25.0	12.1	0.543	0.277-1.067	0.077	0.781	0.374-1.631	0.511
CCRT
Yes	15.4	0.589	0.392-0.885	0.011	0.536	0.355-0.809	0.003
No	9.3	1			1
CA19-9
Elevated	11.5	1.979	1.201-3.261	0.007	1.877	1.077-3.272	0.026
Normal	17	1			1
Albumin
Decreased	6.3	3.033	1.807-5.089	< 0.001	3.148	1.863-5.320	< 0.001
Normal	13.9	1			1

mOS, median overall survival; HR, hazard ratio; CI, confidential interval; BMI, body mass index; CCRT, concurrent chemoradiotherapy; CA19-9, carbohydrate antigen 19-9.

^a) Cox proportional hazard model was performed,

^b) Cox proportional hazard model adjusted for BMI, CCRT, CA 19-9, and albumin was performed.

Table 6.

Analysis of potential prognostic factors for progression-free survival

Clinical factor	mOs (mo)	Univariate analysis			Multivariate analysis
Clinical factor	mOs (mo)	HR	95% CI	p-value^a)	HR	95% CI	p-value^b)
Age (yr)
≥ 60	6.2	1.127	0.740-1.716	0.576	-	-	-
< 60	8.3	1			-
Performance
≥ 2	6	0.969	0.4514-1.826	0.922	-	-	-
0-1	7.7	1			-
T stage
4	8.4	0.432	0.269-0.694	0.001	0.504	0.308-0.825	0.006
3	4.4	1			1
N stage
1	5.2	1.641	1.076-2.502	0.021	1.664	1.049-2.639	0.03
0	8.3	1			1
Site
Corpse	8.0	0.860	0.568-1.304	0.478	-	-	-
Head	6.7	1			-
Size (cm)
≥ 3	7.1	0.969	0.622-1.509	0.889	-	-	-
< 3	7.7	1			-
Initial BMI (kg/m²)				0.030			0.116
< 20.0	5.0	1		Reference	1		Reference
20.0-24.9	8.3	0.527	0.323-0.860	0.010	0.590	0.350-0.995	0.048
≥ 25.0	7.8	0.510	0.250-1.039	0.064	0.822	0.379-1.780	0.618
CCRT
Yes	9.0	0.598	0.389-0.922	0.020	0.667	0.426-1.046	0.078
No	4.4	1			1
CA19-9
Elevated	6.9	1.543	0.944-2.521	0.084	1.295	0.754-2.224	0.349
Normal	10.5	1			1
Albumin
Decreased	3.2	1.658	0.973-2.826	0.063	1.662	0.931-2.969	0.086
Normal	8.0	1			1

mPFS, median progression free survival; HR, hazard ratio; CI, confidential interval; BMI, body mass index; CCRT, concurrent chemoradiotherapy; CA19-9, carbohydrate antigen 19-9.

^a) Cox proportional hazard model was performed,

^b) Cox proportional hazard model adjusted for T stage, N stage, BMI, CCRT, CA 19-9, and albumin was performed.

REFERENCES

1. Kris MG, Benowitz SI, Adams S, Diller L, Ganz P, Kahlenberg MS, et al. Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2010;28:5327–47. Article PubMed
2. Mayahara H, Ito Y, Morizane C, Ueno H, Okusaka T, Kondo S, et al. Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis. BMC Cancer. 2012;12:609.Article PubMed PMC PDF
3. Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorou-racil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer. 1981;48:1705–10. Article PubMed
4. Hariharan D, Saied A, Kocher HM. Analysis of mortality rates for pancreatic cancer across the world. HPB (Oxford). 2008;10:58–62. Article PubMed PMC
5. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst. 1988;80:751–5. PubMed
6. Cohen SJ, Dobelbower R Jr, Lipsitz S, Catalano PJ, Sischy B, Smith TJ, et al. A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys. 2005;62:1345–50. Article PubMed
7. Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouche O, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 2008;19:1592–9. Article PubMed
8. Loehrer PJ Sr, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011;29:4105–12. Article PubMed PMC
9. Huguet F, Andre T, Hammel P, Artru P, Balosso J, Selle F, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007;25:326–31. Article PubMed
10. Bidard FC, Huguet F, Louvet C, Mineur L, Bouche O, Chibaudel B, et al. Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. Ann Oncol. 2013;24:2057–61. Article PubMed
11. Wilkowski R, Boeck S, Ostermaier S, Sauer R, Herbst M, Fietkau R, et al. Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre randomised phase II study. Br J Cancer. 2009;101:1853–9. Article PubMed PMC
12. Zhu CP, Shi J, Chen YX, Xie WF, Lin Y. Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. Radiother Oncol. 2011;99:108–13. Article PubMed
13. Li CP, Chao Y, Chi KH, Chan WK, Teng HC, Lee RC, et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys. 2003;57:98–104. Article PubMed
14. Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013;14:317–26. Article PubMed PMC
15. National Comprehensive Cancer Network. NCCN guidelines for treatment of cancer by site. Fort Washington, PA: National Comprehensive Cancer Network; 2014.
16. Crane CH, Abbruzzese JL, Evans DB, Wolff RA, Ballo MT, Delclos M, et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys. 2002;52:1293–302. Article PubMed
17. Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1985;3:373–8. Article PubMed
18. Krishnan S, Rana V, Janjan NA, Varadhachary GR, Abbruzzese JL, Das P, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer. 2007;110:47–55. Article PubMed
19. Ajani JA, Walsh G, Komaki R, Morris J, Swisher SG, Putnam JB Jr, et al. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer. 2004;100:2347–54. Article PubMed
20. Lloyd S, Chang BW. A comparison of three treatment strategies for locally advanced and borderline resectable pancreatic cancer. J Gastrointest Oncol. 2013;4:123–30. PubMed PMC

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Dose-Escalated SBRT for Borderline and Locally Advanced Pancreatic Cancer: Resectability Rate and Pathological Results of a Multicenter Prospective Study
Barbara Salas-Salas, Laura Ferrera-Alayon, Alberto Espinosa-Lopez, Maria Luisa Perez-Rodriguez, Antonio Alayón Afonso, Andres Vera-Rosas, Gabriel Garcia-Plaza, Rodolfo Chicas-Sett, Maria Soledad Martinez-Martin, Elisa Salcedo, Andrea Kannemann, Marta Llor
Cancers.2025; 17(2): 191. CrossRef
Dose-escalated SBRT for borderline and locally advanced pancreatic cancer. Feasibility, safety and preliminary clinical results of a multicenter study
B. Salas, L. Ferrera-Alayón, A. Espinosa-López, A. Vera-Rosas, E. Salcedo, A. Kannemann, A. Alayon, R. Chicas-Sett, M. LLoret, P.C. Lara
Clinical and Translational Radiation Oncology.2024; 45: 100753. CrossRef
Survival benefits of radiotherapy in locally advanced unresectable and metastatic pancreatic cancer: a single-institution cohort and SEER database analysis
Bi-Yang Cao, Le-Tian Zhang, Chen-Chen Wu, Jing Wang, Lin Yang
Frontiers in Oncology.2024;[Epub] CrossRef
Comparing concurrent chemoradiotherapy, 125I seed implantation combined with chemotherapy, and chemotherapy alone efficacy in treating unresectable locally advanced pancreatic cancer
Yanfen Zheng, Rui Huang, Wenxue Zou, Chao Liu, Hongxin Niu, Jinbo Yue
Precision Radiation Oncology.2022; 6(2): 144. CrossRef
Concurrent Nab-paclitaxel and Radiotherapy
William T. Arscott, Kevin T. Nead, Adham Bear, Sriram Venigalla, Jacob Shabason, John N. Lukens, John P. Plastaras, Andrzej Wojcieszynski, James Metz, Mark O’Hara, Kim A. Reiss, Ursina Teitelbaum, Arturo Loaiza-Bonilla, Jeffrey Drebin, Major K. Lee, Stuti
American Journal of Clinical Oncology.2021; 44(9): 469. CrossRef
Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer
Mei Hua Jin, Ah-Rong Nam, Ji Eun Park, Ju-Hee Bang, Yung-Jue Bang, Do-Youn Oh
Cancer Research and Treatment.2020; 52(1): 149. CrossRef
Current trends and issues of conversion surgery for patients with locally advanced unresectable pancreatic cancer
Toshimichi ASANO, Satoshi HIRANO, Toru NAKAMURA, Takehiro NOJI, Keisuke OKAMURA, Takahiro TSUCHIKAWA, Yuma EBIHARA, Toshiaki SHICHINOHE
Suizo.2018; 33(1): 48. CrossRef
Survival benefit of conversion surgery for patients with initially unresectable pancreatic cancer who responded favorably to nonsurgical treatment
Toshimichi Asano, Satoshi Hirano, Toru Nakamura, Keisuke Okamura, Takahiro Tsuchikawa, Takehiro Noji, Yoshitsugu Nakanishi, Kimitaka Tanaka, Toshiaki Shichinohe
Journal of Hepato-Biliary-Pancreatic Sciences.2018; 25(7): 342. CrossRef
Which patients with locally advanced pancreatic cancer treated with induction chemotherapy are most likely to benefit from post-induction chemoradiotherapy?
Sophie Otter, Irene Chong, Ria Kalaitzaki, Diana Tait
International Journal of Hepatobiliary and Pancreatic Diseases.2018; 8(1): 1. CrossRef
Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy
Yi-Jun Kim, Hyeon Kang Koh, Eui Kyu Chie, Do-Youn Oh, Yung-Jue Bang, Eun Mi Nam, Kyubo Kim
International Journal of Clinical Oncology.2017; 22(6): 1069. CrossRef
Risk factors of liver metastasis from advanced pancreatic adenocarcinoma: a large multicenter cohort study
Dong S., Wang L., Guo Y. B., Ying H. F., Shen X. H., Meng Z. Q., Chen Hao, Chen Q. W., Li Z. S.
World Journal of Surgical Oncology.2017;[Epub] CrossRef
Risk factors for latent distant organ metastasis detected by staging laparoscopy in patients with radiologically defined locally advanced pancreatic ductal adenocarcinoma
Ilhan Karabicak, Sohei Satoi, Hiroaki Yanagimoto, Tomohisa Yamamoto, Satoshi Hirooka, So Yamaki, Hisashi Kosaka, Kentaro Inoue, Yoichi Matsui, Masanori Kon
Journal of Hepato-Biliary-Pancreatic Sciences.2016; 23(12): 750. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study

Cancer Res Treat. 2016;48(3):1045-1055. Published online October 16, 2015

DOI: https://doi.org/10.4143/crt.2015.226

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Conclusion
NOTES
REFERENCES

Combined High-Dose Radiotherapy with Sequential Gemcitabine-Cisplatin Based Chemotherapy Increase the Resectability and Survival in Locally Advanced Unresectable Intrahepatic Cholangiocarcinoma: A Multi-institutional Cohort Study

Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study

Fig. 1. Flow diagram for the study cohort. LAPC, locally advanced pancreatic cancer; CCRT, concurrent chemoradiotherapy, CA, chemotherapy alone.

Fig. 2. Overall survival (OS) and progression-free survival (PFS) by first-line treatment modality. (A) Median OS was 15.4 months (95% confidence interval [CI], 13.2 to 17.6 months) in the concurrent chemoradiotherapy (CCRT) group and 9.3 months (95% CI, 6.6 to 12.0 months) in the chemotherapy alone (CA) group (p=0.011). (B) Median PFS was 9.0 months (95% CI, 7.0 to 11.0 months) in the CCRT group and 4.0 months (95% CI, 1.6 to 6.3 months) in the CA group (p=0.010).

Fig. 1.

Fig. 2.

Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study

Characteristic	CCRT vs. CA		Total (n=107)	p-value^a)
Characteristic	CCRT (n=63)	CA (n=44)	Total (n=107)	p-value^a)
Sex
Male	33 (52.4)	20 (45.5)	53 (49.5)	0.557
Female	30 (47.6)	24 (54.5)	54 (50.5)
Age (yr)
≥ 60	30 (47.6)	29 (65.9)	59 (55.1)	0.076
< 60	33 (52.4)	15 (34.1)	48 (44.9)
Performance
0-1	57 (86.4)	38 (86.4)	95 (88.8)	0.546
≥ 2	6 (9.6)0	6 (13.6)	12 (11.2)
T stage
3	14 (22.2)	17 (38.6)	31 (29.0)	0.084
4	49 (77.8)	27 (61.4)	76 (71.0)
N stage
0	41 (65.1)	21 (47.7)	62 (57.9)	0.111
1	22 (34.9)	23 (52.3)	45 (42.1)
Site
Head	29 (46.0)	26 (59.1)	55 (51.4)	0.239
Corpse	34 (54.0)	18 (40.9)	52 (48.6)
Size (cm)
≥ 3	41 (65.1)	32 (72.7)	73 (68.2)	0.527
< 3	22 (34.9)	12 (27.3)	34 (31.8)
Initial BMI (kg/m²)
< 20.0	19 (30.2)	12 (27.3)	31 (29.0)	0.924
20.0-24.9	36 (57.1)	25 (56.8)	61 (57.0)
≥ 25.0	8 (12.7)	7 (15.9)	15 (14.0)
CA19-9
Elevated	46 (73.0)	37 (84.1)	83 (77.6)	0.240
Normal	17 (27.0)	7 (15.9)	24 (22.4)
Albumin
Decreased	11 (17.5)	10 (22.7)	21 (19.6)	0.622
Normal	52 (82.5)	34 (77.3)	86 (80.4)
No. of chemotherapy regimens
1	31 (49.2)	29 (65.9)	60 (56.1)	0.114
≥ 2	32 (50.8)	15 (34.1)	47 (43.9)

Characteristic	No. of patients (%)
CCRT group (n=63)
Induction chemotherapy (n=63)
Administered	36 (57.1)
Not administered	27 (42.9)
DI of induction chemotherapy (%) (n=36)
100	18 (50.0)
< 100	18 (50.0)
Agents of induction chemotherapy (n=36)
Gemcitabine/cisplatin	31 (86.1)
Gemcitabine/capecitabine	1 (2.8)
Gemcitabine/oxaliplatin	1 (2.8)
Gemcitabine alone	3 (8.3)
Radiosensitizer (n=63)
Gemcitabine	17 (27.0)
5-FU	16 (25.4)
Capecitabine	30 (47.6)
Total radiation dose (Gy) (n=63)
< 50	7 (11.1)
50-60	56 (88.9)
Radiation dose per fraction (Gy) (n=63)
1.6	1 (1.6)
1.8	52 (82.5)
2	10 (15.9)
Maintenance chemotherapy (n=63)
Administered	44 (69.8)
Not administered	19 (30.2)
DI of maintenance chemotherapy (%) (n=44)
100	23 (52.3)
< 100 (70-87.5)	21 (47.7)
Agents of maintenance chemotherapy (n=44)
Gemcitabine/cisplatin	9 (20.4)
Gemcitabine/capecitabine	3 (6.8)
Gemcitabine/5-FU	1 (2.3)
Gemcitabine alone	25 (56.8)
5-FU/leucovorin	4 (9.1)
5-FU/cisplatin	1 (2.3)
Capecitabine alone	1 (2.3)
CA group (n=44)
DI of chemotherapy (%) (n=44)
100	28 (63.6)
< 100 (70-87.5)	16 (36.4)
Agents of chemotherapy (n=44)
Gemcitabine/cisplatin	18 (40.9)
Gemcitabine/capecitabine	10 (22.7)
Gemcitabine/oxaliplatin	4 (9.1)
Gemcitabine/erlotinib	2 (4.5)
Gemcitabine/capecitabine/erlotinib	1 (2.3)
Gemcitabine/S-1	1 (2.3)
Gemcitabine alone	7 (15.9)
S-1	1 (2.3)

Characteristic	No. of patients (%)
CCRT group (n=61)
Treatment scheme (n=61)
CCRT alone	10 (16.4)
Induction-CCRT	8 (13.1)
CCRT-maintenance	15 (24.6)
Induction-CCRT-maintenance	28 (45.9)
BR to induction chemotherapy (n=36)
PR	5 (13.9)
SD	31 (86.1)
BR to CCRT (n=61)
CR	1 (1.6)
PR	15 (24.6)
SD	39 (64.0)
PD	6 (9.8)
BR to entire CCRT regimen (n=61)
CR	3 (4.9)
PR	18 (29.5)
SD	37 (60.7)
PD	3 (4.9)
Pattern of failure (n=59)
Local	21 (35.6)
Systemic	23 (39.0)
Both	7 (11.9)
NA	8 (13.5)
CA group (n=44)
BR to first-line treatment (n=44)
CR	1 (2.3)
PR	7 (15.9)
SD	18 (40.9)
PD	12 (27.3)
NA	6 (13.6)
Pattern of failure (n=43)
Local	12 (27.3)
Systemic	13 (29.5)
Both	4 (9.1)
NA	14 (34.1)

Characteristic	CCRT vs. CA (n==105)		p-value
Characteristic	CCRT (n=61)	CA (n=44)	p-value
First-line treatment	61	44
Best response
ORR	21 (34.4)	8 (18.2)	0.079^a)
DCR	58 (95.1)	26 (59.1)	< 0.001^a)
Pattern of PD (of accessible patients) (n=82)
Local	28 (54.9)	17 (58.6)	0.817^a)
Systemic	30 (58.8)	17 (58.6)	1.000^a)
Median survival (mo)
First-line PFS (95% CI)	9.0 (7.0-11.0)	4.4 (0.9-8.0)	0.020^b)
Time to local failure (95% CI) (n=46)	10.5 (8.5-12.4)	3.7 (1.4-5.9)	0.001^b)
Time to distant failure (95% CI) (n=48)	7.8 (5.1-10.5)	5.0 (1.6-8.4)	0.001^b)
OS (95% CI) (n=107)	15.4 (13.2-17.6)	9.3 (6.6-12.0)	0.011^b)

Clinical factor	mOS (mo)	Univariate analysis			Multivariate analysis
Clinical factor	mOS (mo)	HR	95% CI	p-value^a)	HR	95% CI	p-value^b)
Age (yr)
≥ 60	-	1.135	0.759-1.698	0.536	-	-	-
< 60	-	1			-
Performance
≥ 2	-	1.434	0.760-2.707	0.266	-	-	-
0-1	-	1			-
T stage
4	-	0.961	0.616-1.499	0.861	-	-	-
3	-	1			-
N stage
1	-	1.165	0.776-1.749	0.462	-	-	-
0	-	1			-
Site
Corpse	-	0.816	0.547-1.217	0.319	-	-	-
Head	-	1			-
Size (cm)
≥ 3	-	1.302	0.841-2.014	0.236	-	-	-
< 3	-	1			-
Initial BMI (kg/m²)				0.021			0.097
< 20.0	10.7	1		Reference	1		Reference
20.0-24.9	14.2	0.532	0.337-0.840	0.007	0.601	0.374-0.965	0.035
≥ 25.0	12.1	0.543	0.277-1.067	0.077	0.781	0.374-1.631	0.511
CCRT
Yes	15.4	0.589	0.392-0.885	0.011	0.536	0.355-0.809	0.003
No	9.3	1			1
CA19-9
Elevated	11.5	1.979	1.201-3.261	0.007	1.877	1.077-3.272	0.026
Normal	17	1			1
Albumin
Decreased	6.3	3.033	1.807-5.089	< 0.001	3.148	1.863-5.320	< 0.001
Normal	13.9	1			1

Clinical factor	mOs (mo)	Univariate analysis			Multivariate analysis
Clinical factor	mOs (mo)	HR	95% CI	p-value^a)	HR	95% CI	p-value^b)
Age (yr)
≥ 60	6.2	1.127	0.740-1.716	0.576	-	-	-
< 60	8.3	1			-
Performance
≥ 2	6	0.969	0.4514-1.826	0.922	-	-	-
0-1	7.7	1			-
T stage
4	8.4	0.432	0.269-0.694	0.001	0.504	0.308-0.825	0.006
3	4.4	1			1
N stage
1	5.2	1.641	1.076-2.502	0.021	1.664	1.049-2.639	0.03
0	8.3	1			1
Site
Corpse	8.0	0.860	0.568-1.304	0.478	-	-	-
Head	6.7	1			-
Size (cm)
≥ 3	7.1	0.969	0.622-1.509	0.889	-	-	-
< 3	7.7	1			-
Initial BMI (kg/m²)				0.030			0.116
< 20.0	5.0	1		Reference	1		Reference
20.0-24.9	8.3	0.527	0.323-0.860	0.010	0.590	0.350-0.995	0.048
≥ 25.0	7.8	0.510	0.250-1.039	0.064	0.822	0.379-1.780	0.618
CCRT
Yes	9.0	0.598	0.389-0.922	0.020	0.667	0.426-1.046	0.078
No	4.4	1			1
CA19-9
Elevated	6.9	1.543	0.944-2.521	0.084	1.295	0.754-2.224	0.349
Normal	10.5	1			1
Albumin
Decreased	3.2	1.658	0.973-2.826	0.063	1.662	0.931-2.969	0.086
Normal	8.0	1			1

Table 1. Clinical characteristics by treatment groups

Values are presented as number (%). CCRT, concurrent chemoradiotherapy; CA, chemotherapy alone; BMI, body mass index; CA19-9, carbohydrate antigen 19-9.

Fisher exact test was performed.

Table 2. Details of treatment regimens

CCRT, concurrent chemoradiotherapy; 5-FU, 5-fluorouracil; DI, dose intensity; CA, chemotherapy alone.

Table 3. Response to first-line treatment

CCRT, concurrent chemoradiotherapy; BR, best response; PR, partial response; SD, stable disease; CR, complete response; PD, progressive disease; NA, not assessable; CA, chemotherapy alone.

Table 4. Summary of response and survival by treatment groups

Fisher exact test was performed,

Log-rank test was performed.

Table 5. Analysis of potential prognostic factors for overall survival

mOS, median overall survival; HR, hazard ratio; CI, confidential interval; BMI, body mass index; CCRT, concurrent chemoradiotherapy; CA19-9, carbohydrate antigen 19-9.

Cox proportional hazard model was performed,

Cox proportional hazard model adjusted for BMI, CCRT, CA 19-9, and albumin was performed.

Table 6. Analysis of potential prognostic factors for progression-free survival

mPFS, median progression free survival; HR, hazard ratio; CI, confidential interval; BMI, body mass index; CCRT, concurrent chemoradiotherapy; CA19-9, carbohydrate antigen 19-9.

Cox proportional hazard model was performed,

Cox proportional hazard model adjusted for T stage, N stage, BMI, CCRT, CA 19-9, and albumin was performed.